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The p53 wild-type protein plays an important role in cells as is shown by its fine regulation at diﬀerent levels. Since its discovery,
numerous mutations have been described. In breast cancers, p53 is mutated in almost 30% of cases, with a higher frequency in
some tumor subtypes. TP53 mutation is reported to be a factor for good prognosis in some studies, while in others it is a factor for
poor prognosis. The explanation for these diﬀerent results could be linked to the fact that the studies were performed on diﬀerent
tumor types and with diﬀerent therapy regimens.
1. Introduction
Breast cancer aﬀects more than onemillion patients annually
in the world and is a leading cause of mortality [1].
The prognosis of patients with localized breast cancer is
determined by clinical and biological factors such as age
at diagnosis, tumor size, nodal status, tumor histological
grading, expression of estrogen/progesterone receptors [2],
and Her2 status. Treatments combine surgery on the primary
tumor, radiation therapy of the breast, chemotherapy, and
hormone therapy.
In adjuvant setting, the benefit of chemotherapy has been
confirmed since the 1980s by the 5-yearly meta-analyses
of the Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG), particularly in women under 50 years [3]. Adju-
vant regimens include mainly anthracyclines and taxanes
[4]. In patients with localized breast cancer overexpressing
Her2, trastuzumab has been proven to significantly increase
survival [5]. In patients with estrogen receptor (ER-) positive
tumors, addition of hormone therapy such as tamoxifen
or aromatase inhibitors significantly decreases the risk of
recurrence and increases survival [3, 6].
The same chemotherapeutic agents and hormone thera-
pies are currently used for patients with metastatic disease.
Despite a clear benefit of these medical treatments in terms
of survival, median overall survival ranges from 31–39
months [7, 8], In addition, 20–40% patients exhibit primary
resistance to medical treatment [7–9] suggesting that we
need better knowledge of the predictive factors of response to
treatment (chemotherapy, hormone therapy, radiotherapy).
In this paper, we review the relationship between TP53 status
in breast cancers and response to treatment.
2. The Biology of TP53
In 1979, three teams led by A. Levine, P. May and L. Old
discovered the p53 protein, a protein that is, highly conserved
across animal species, which is encoded by the TP53 gene
located on the short arm of chromosome 17 (17p13.1). Its
sequence, about 20 Kb, contains 11 exons, but the first exon
does not encode and is located about 10 Kb from other exons
[10]. In 1989, Vogelstein’s team discovered that the TP53
gene is inactivated in human cancers [11].
The p53 protein contains 393 amino acids (AA), is
divided into regions highly conserved during evolution [12],
and its role in numerous regulatory mechanisms has been
well established. The protein is composed of: (i) an N-
terminal region (AA 1–42), (ii) a region rich in proline
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Figure 1: The p53 protein structure. The N-terminal region contains the transactivation domain (AA 1–62) and a proline-rich region
(residues 63–97) with a role in apoptosis. The central domain (the core domain, AA 102–292) contains specific DNA sites. The C-terminal
region includes the tetramerization domain (AA 325–360) and a negative autoregulatory domain. NES signals exist on both N- and C-
terminal, whereas NLS signals are located on C-terminal region.

















































•←D N A d a m a g e s 
( c h e m o t h e r a p e u t i c d r u g s , 
i o n i s i n g a n d U V r a d i a t i o n s ) 
•←V i r a l o n c o g e n e s 
•←H y p o x i a 
Eﬀects
Figure 2: Stimuli and eﬀects of activation of p53 protein. In
response to diverse stimuli p53 functional protein induces diverse
eﬀects such as cell cycle arrest, apoptosis, repair of DNA lesions,
senescence, and autophagy.
residues (AA 63–97) involved in the induction of apoptosis
[13], (iii) a core domain necessary for binding to DNA (AA
102–292), containing most of the inactivating mutations
found in diﬀerent types of human cancers [14], (iv) a
tetramerization domain (AA 323–356), and (v) a C-terminal
region (AA 363–393). This C-terminal region of p53 binds
to the N-terminal domain of Mdm2 (murine double minute
2). In addition, there are also sequences for exporting to
the cytoplasm at the N- and C-terminal ends (NES, nuclear
export signal), as well as nuclear localization sequences at the
C-terminal end (NLS, nuclear localization signal), enabling
the regulation of subcellular localization of p53 [15, 16]
(Figure 1).
3. Stimuli and Activation Effects of TP53
Multiple stimuli such as ionizing radiations, DNA lesions,
nitric oxide, hypoxia, chemotherapeutic agents, or oncogenic
stimuli can activate 53 [17, 18] (Figure 2). In response to
various stimuli, p53 undergoes diﬀerent changes and this
activation could induce diﬀerent eﬀects. p53 is a tran-
scription factor involved in the control of G1/S and G2/M
phase transition, in DNA repair, and in induction of
senescence, apoptosis, autophagy, mitotic catastrophe, and
angiogenesis.
3.1. Cell Cycle Regulation. TP53 regulates the control of the
G1 checkpoint and can induce an arrest of the cell cycle,
repair or apoptosis if DNA lesions are extensive [19]. Wild-
type p53 protein can transcriptionally transactivate p21Cip1,
a potent inhibitor ofmost cyclin-dependent kinases, involved
in the cell cycle arrest [20]. p53 also stimulates the expression
of the 14-3-3σ protein that sequesters the cyclin B1/CDK1
complex to block the transition G2/M. But p53 also induces
the expression of many others genes such as GADD45, which
interacts with PCNA to inhibit the passage to S phase, or
Reprimo to block the cell cycle in G2 phase [21].
3.2. Cell Senescence. Cellular senescence is thought to play
an important role in tumor suppression and to contribute
to cellular aging [22]. The p53 tumor suppressor is also a
critical mediator of senescence, and it seems to play a critical
role in the induction and maintenance of cellular senescence.
The first information about the importance of p53 on cell
senescence was provided by the studies using T antigens
of SV40 virus which inactivate p53. p53-null fibroblasts
remain immortal when propagated in vitro. p53 activation
is an essential step in the induction of senescence following
DNA damage or other forms of stress. In the context of
senescence, p53 is controlled by ATM/ATR and Chk1/Chk2
proteins which cause the posttranslational stabilization of
p53 through its phosphorylation [23].
3.3. Apoptosis. Apoptosis is one of the principal functions of
p53. It has been shown that p53 can transactivate the cell
death receptors CD95 or TNF which induce the formation
of the DISC complex and finally activate caspase 8. p53
also activates proapoptotic members of the Bcl2 family: Bax,
Noxa, and Puma-involved in the permeabilization of the
outer mitochondrial membrane [24]. Moreover, p53 has
also been reported to have a direct role in cell death initia-
tion by localizing to mitochondria and regulating mitochon-
drial outer membrane permeabilisation directly. Thus, p53
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Figure 3: Detection of p53 by immunohystochemistry and determination of TP53 status by FASAY test. Immunohystochemistry (IHC) is
not the best method to determine p53 status. Thus, four diﬀerent situations are illustrated: (a) p53 is negative on IHC and not mutated on
FASAY test; (b) p53 is positive on IHC and mutated on FASAY test (red colonies); (c) p53 is weakly positive on IHC but not mutated on
FASAY test (white colonies); (d) p53 is negative on IHC but mutated on FASAY test (for exemple codon Stop on exon 5); Magnification x400.
p53 antibody (clone DO-7, DakoCytomation, France) was used.
protein can directly induce permeabilisation of the outer
mitochondrial membrane by forming complexes with the
protective BclXL and Bcl2 proteins, resulting in cytochrome
C release [25, 26].
3.4. Autophagy. Autophagy is a process suppressing tumor
initiation and reducing genomic instability. Autophagy con-
sists in the lysosomal degradation of intracellular compo-
nents leading to the generation of new metabolic substrates,
thus favouring adaptation to stress and cell survival [27]. p53
can activate but also inhibit autophagy. Under stress, p53 can
activate its target gene in the nucleus, such as AMPK β1 and
β2 (AMP-activated protein kinase) [28], DAPK-1 (death-
associated protein kinase1), and DRAM (damage-regulated
autophagy modulator) [29]. Cytoplasmic, but not nuclear,
p53 is able to repress autophagy [30, 31].
3.5. Mitotic Catastrophe. Mitotic catastrophe is a biological
state that precedes cell death. In response to DNA damage,
checkpoints are activated to delay cell cycle progression and
to coordinate repair. Reports have suggested that the absence
of p53 might increase mitotic catastrophe [32]. p53-deficient
cells in an unchecked tetraploid G1 state reduplicate their
DNA, leading to polyploidy and subsequent chromosomal
instability. In the presence of wild-type p53, the polyploidy
causes the activation of p21CIP1 and an irreversible arrest
in the cell cycle, or in cell death, thus preventing the
propagation of aneuploidy [33].
3.6. Angiogenesis. The formation of new blood capillaries
(angiogenesis) is closely regulated by proangiogenic and
antiangiogenic factors [34]. The p53 protein has been shown
to limit angiogenesis by few mechanisms: (1) interfering
with central regulators of hypoxia that mediate angiogenesis,
(2) inhibiting the production of proangiogenic factors, and
(3) directly increasing the production of endogenous angi-
ogenesis inhibitors. The combination of these eﬀects allows
p53 to eﬃciently shut down the angiogenic potential of
cancer cells [35]. Wild-type p53 plays a role in limiting
tumor vascularization as demonstrated by some clinical
studies [36]. Mutant p53 plays a central role in promoting
angiogenesis in colon cancer progression [37], and tumors
carrying p53 mutations are more highly vascularised than
tumors harboring wild-type p53. The loss of TP53 appears to
amplify the HIF (Hypoxia Inducible Factor) pathway. HIF-
1α has been shown to be physically associated with p53 in
immuno-precipitation experiments. p53 promotes MDM2-
mediated ubiquitination and degradation of HIF-1α, while
loss of p53 leads to amplification of the HIF response [38].
4. Regulation of p53
The protein p53 can be regulated at diﬀerent levels:
(i) by posttranslational modifications, such as phospho-
rylation, sumoylation, or acetylation of the protein
[39, 40],
(ii) by increasing the protein concentration: one of the
key regulators of p53 is Mdm2 which targets p53 for
breakdown by the proteasome [41],
(iii) by cellular localization: import and nuclear export is
closely regulated because the functions of p53 depend
on its nuclear localization. Eﬃcient transfer to the
cytoplasm depends on Mdm2 forming a complex
with p53, which is why ubiquitin ligase activity of
Mdm2 is essential for nuclear export of p53 [42].
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The ubiquitinilation of p53 by Mdm2 occurs in
the C-terminus domain, and it has been shown
that mutations in lysine residues inhibit the nuclear
export of p53 by Mdm2 [15].
5. Detection of p53
Under normal conditions, p53 protein remains undetectable
due to its short half-life (Figure 3(a)). In contrast, mutant
proteins accumulate in the nucleus of tumor cells due to
increased half-life and an altered conformational structure
(Figure 3(b)).
In a large majority of studies, detection of p53 is
highlighted by the protein in the nucleus using immuno-
histochemistry techniques. This method of detection could
give false positive results from stabilization of wild-type p53
proteins due to cellular stress (Figure 3(c)) or could give false
negatives due to codon stop, frameshifts, or other destabi-
lizing mutations (Figure 3(d)). Lack of immunostaining for
p53 despite mutation of the TP53 gene was particularly seen
in tumors harboring nonsense mutations or deletions/splices
[43] while other studies have shown that the identification of
positivity for p53 solely detected by immunohistochemistry
did not always reflect a p53 mutation [44].
Another way to determine TP53 status is the FASAY test
(Functional Analysis of Separated Alleles in Yeast) [45]. After
the extraction of mRNA from whole blood or from tissue
(normal or tumoral) reverse transcription by RT-PCR is
carried out. The DNA binding domain is amplified and the
PCR product is cloned by homologous recombination into
yeast with a linearized expression plasmid vector carrying
the 5′ and 3′ ends of the TP53 open reading frame. The
plasmid, thus, has a constitutive expression of human TP53.
The yeast contains an open reading frame (ORF) for adenine
regulated by a promoter under the control of TP53. The
yeasts are selected on a selective medium lacking leucine,
but containing adenine. When TP53 is wild-type, a complete
metabolism of adenine occurs and the colonies are white.
The cells containing mutant TP53 fail to express adenine,
and, consequently, the colonies are red because of the
accumulation of an intermediate adenine metabolite. These
colonies are also smaller than normal because adenine limits
growth. Thus, the TP53 status can be easily determined by
the color of transfected yeast cells [45].
Some studies analyzed TP53 status in breast tumors using
a robust and sensitive approach combining three diﬀer-
ent methods: p53 immunohistochemistry, FASAY test, and
sequencing of the coding sequence. Tumors were considered
TP53 mutant when (i) more than 15% of the yeast colonies
were red (ii) analysis using the split versions of the test
could identify the defect in the 5′ or 3′ parts of the gene,
and (iii) sequence analysis from mutant yeast colonies could
identify an unambiguous genetic defect (mutation, deletion,
splicing defects) [46]. FASAY provided a major contribution
to the analysis by revealing several TP53 mutations not
detected by direct sequencing, principally in samples highly
contaminated with stromal cells [47, 48].
6. TP53 Mutations
The function of p53 is altered in nearly 50% of cancers,
p53 being inactivated by mutations in the DNA binding
domain or deletion of the carboxy-terminal domain [49].
In other cases, loss of p53 function is related to other
mechanisms such as interaction with a viral protein (in
lymphoma, hepatocellular carcinoma), multiplication of the
MDM2 gene (in sarcomas), and deletion of p14ARF gene (in
breast or lung tumors) [50].
p53 transcriptional activity is based on the formation
of tetramers (dimers of dimers). Mutant proteins may
interfere with wild-type p53 by forming hetero-oligomers
that are less competent for specific DNA binding [51].
It has been shown that some missense mutations gain
oncogenic properties. In the experimental procedure, the
authors introduced common TP53 cancer mutations R248W
and R273H, into the humanized p53 knock-in allele in mice.
They demonstrate that the tumour-suppressor functions of
p53 were abolished in p53-mutant mice. Moreover, inter-
chromosomal translocations were observed [52]. Mutants
p53, mutants R248W, and R273H interact with Mre11 and
inactivate Mre11/ATM-dependent DNA damage responses,
leading to chromosomal translocation and defective G2/M
checkpoint [53]. The analysis of the spectrum of TP53
somatic mutations in human cancers shows an association
between exposure to diﬀerent types of carcinogens and the
development of various cancers. TP53 mutations are mostly
missense point mutations and are located in 80% to 90%
of cases in the central region encoding the DNA binding
domain [51, 54]. Some mutations are found much more
often than others. Thus, the following six mutations account
for about 30% of all mutations: 175Arg–His, 248Arg–Gln,
273Arg–His, 248Arg–Trp, 273Cys–Arg and 282Arg–Trp [13].
The universal mutation database (http://www-p53.iarc)
contains 30,500mutations [55]. Thus, mutaions are found in
20–30% of malignant melanomas [56], in 50% of superficial
bladder cancers, in 29% of nonsmall cell lung cancers [57],
in 58% of hepatocellular carcinomas [58], and in 25% of
breast cancers [59]. Thirty-seven percent of the myeloma
patients with del (17p) present a TP53 mutation versus
0% of patients lacking the del(17p), but the prognostic
significance of these mutations remains to be evaluated [60].
The loss of p53 tumor suppressor activity is associated with
a poor prognosis in mantle cell lymphoma [61].
7. TP53 Status and Prognosis in Breast Cancer
Breast cancer is a heterogeneous disease. Histological type,
grade, tumor size, lymph node involvement, and estrogen
receptor and HER-2 receptor status, all influence prognosis
and the probability of response to systemic therapies [62].
TP53 is mutated in about 30% of breast cancers [59].
The possible links between alterations of p53 and clinical
or pathological features of breast tumors have been widely
investigated.
The first study to examine gene-expression patterns of
breast cancer suggested that at least four major molecular
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classes of breast cancer exist: luminal-like, basal-like, normal-
like, and HER-2 positive [63]. Basal-like breast cancers
account for 15% of breast cancers and are often described
as triple negative breast cancers (TNBCs). In fact, TNBCs,
defined by lack of expression of estrogen receptor, pro-
gesterone receptor, and HER2 [64], probably include both
basal-like breast cancers and some poorly diﬀerentiated
luminal breast cancers [65]. They are also associated with a
younger age and a poor prognosis [66]. TNBCs also have an
increased frequency of TP53 mutations [67]. Recently, it was
shown that p53 status was a strongly unfavorable prognostic
factor for relapse-free survival and overall survival only in
a triple negative group in patients treated with adjuvant
anthracycline-containing chemotherapy. Under this treat-
ment, expression of p53 provides information concerning
poor outcome in triple-negative tumors [67, 68].
HER2-like tumors show an increased expression of
genes associated with ErbB2 amplicon and TP53 mutation
[69]. The simultaneous immunodetection of p53/ErbB2
appears to have greater negative prognostic relevance [70].
Other data are consistent with the hypothesis that certain
TP53 mutations and ErbB2 overexpression are predictive of
resistance to doxorubicin in patients with breast cancer [43].
Inflammatory breast cancer (IBC) is a clinical diagnosis
known as the T4d category in the TNM classification [71].
It is a distinct clinical subtype of locally advanced breast
cancer (LABC), with a particularly aggressive behaviour and
poor prognosis [72]. TP53 mutations are more frequent in
inflammatory breast cancer (50%) than in noninflammatory
breast cancer (20–30%) [73, 74]. Interpretation of prognostic
data is complicated by the fact that earlier studies only
used immunohistochemistry to detect the accumulation of
p53. Breast tumors with positive immunostaining for p53
are usually ER and PR negative. This is often associated
with a high rate of proliferation, a high histological grade,
aneuploidy, and a poor prognosis [75, 76]. A prognostic
value of TP53 mutation by sequencing was found in more
than 25 studies analyzing 6000 patients [46]. Moreover, the
prognostic significance of TP53 mutation depends on the
specificity of the mutation [77].
7.1. p53 Status and Anthracycline Chemotherapy in Breast
Cancer. In 50 noninflammatory locally advanced breast
cancers that were treated with dose-intense epirubicin-
cyclophosphamide combination, eight complete patholog-
ical response (pCR) were shown in the 14 patients with
tumors containing mutated TP53, whereas none of the 36
patients with a wild-type TP53 status had a pCR after
chemotherapy [78]. In 80 patients with noninflammatory
breast cancers treated with front-line chemotherapy com-
prising epirubicin and cyclophosphamide, 28 had TP53-
mutant tumors. Fifteen out of these 28 patients exhibited
pCR while none of the 52 patients with TP53 wild-
type tumors had a pCR. Moreover, nine out of ten of
the highly aggressive basal subtypes showed pCRs. This
demonstrates that, in noninflammatory breast cancers, TP53
status could be a key predictive factor for response to
this chemotherapy treatment and further suggests that the
basal subtype is exquisitely sensitive to this association [79].
Research on stage II-III breast cancer patients treated front
line with epirubicin-based regimens of various cyclophos-
phamide dose intensities suggest that cyclophosphamide
dose intensification in ER negative and TP53 mutated
patients could significantly improve their response [80].
All these studies show an increased response in tumors
with a mutation in TP53. Recently, it was shown on in
vivo models that epirubicin-cyclophosphamide treatment
induces senescence-like features in TP53 wild-type tumor,
probably accounting for cell cycle arrest and subsequent
resistance to treatment. Conversely in TP53 mutated tumors,
chemotherapy induces mitotic catastrophe and tumor death,
accounting for complete response to this association exclu-
sively in patients with TP53 mutated tumors [81].
In contrast, in a study on 63 patients with locally
advanced breast cancer and treated with doxorubicin, a
correlation was observed between the presence of muta-
tions in the zinc finger domain of the p53 protein and
resistance to treatment [82]. These results were confirmed
in another study involving 90 patients [43]. Some clinical
studies showed that mutant p53 confers chemoresistance in
patients with breast cancer. Patients with missense mutations
located in zinc-binding regions had significantly decreased
disease-free and overall survival relative to patients whose
tumors had mutations in other domains [83]. It has been
suggested that codon polymorphism 72 (Arg/Pro) could
aﬀect the response to chemotherapy in tumor cells through
the interaction between p53 and p73 [84]. Protein p73
belongs to the same family as p53 and p63 and shows a
striking homology within both the DNA binding domain
and oligomerization domain. P73 presents a wide array of
splicing variants α, β, γ, δ, ε, ζ [85]. p73 has proapoptotic and
antiapoptotic properties. p73alphamRNAs encode two types
of isoform (TAp73alpha and DeltaNp73alpha) resulting
from the use of two diﬀerent promoters, and eliciting or lack-
ing NH(2)-terminal transactivation domain, respectively.
DeltaNp73alpha inhibits p53 proapoptotic function [86].
Patients with breast cancer with a variant Pro/Pro TP53 are
less sensitive to anthracycline-based therapy than those with
a variant Pro/Arg or Arg/Arg [87]. These studies show that
mutations in TP53 could induce a resistance to treatment
based on anthracyclines.
These results are not contradictory, they rather result
from studies exploring diﬀerent tumor types and diﬀerent
regimens. TP53 status may have a diﬀerent predictive value
for eﬃcacy of anthracycline/alkylating agents-based regimen
in each molecular subclass [88]. In 630 patients with breast
cancer, the clinical outcome was significantly diﬀerent for
diﬀerent TP53 mutation types but also for diﬀerent tumors
[89].
7.2. p53 Status and Nonanthracycline Chemotherapy in
Breast Cancer. In 67 tumors treated with 5-FU, epirubicin,
cyclophosphamide, or paclitaxel, combined sequencing and
immunohistochemistry showed a significant association
between the presence of TP53 mutation and response to
paclitaxel. The eﬃcacy of paclitaxel during mitosis is induced
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by the fact that there is no stop in G1 phase, because
of absence of p53 [46]. Trastuzumab, an HER2-targeted
monoclonal antibody, induces growth arrest and apoptosis
in a p53-independent manner. A retrospective study on 104
patients receiving trastuzumab shows that p53 status is not a
predictor of the clinical eﬃcacy [90].
Some studies suggested that p53 may influence response
to antihormonal treatments. TP53 mutations are less fre-
quent in patients with ER-positive breast cancers, but they
are associated with a poorer prognostic in these patients.
In vitro studies on human breast cancer cell lines, MN1
(p53WT) and MDD2 (p53MUT) derived from MCF-7, it
was shown that p53 mutated cells were more resistant to
cytotoxic eﬀects of 4-hydroxy-tamoxifen compared to p53
wild-type cells [91]. Clinical studies on patients with locally
advanced breast cancer treated with tamoxifen or primary
chemotherapy showed that mutations in the TP53 gene are
associated with a poor survival [92]. In a meta-analysis of
4,683 patients with breast cancer, the overexpression of p53
was correlated with poor outcome in premenopausal women
treated with tamoxifen after chemotherapy [93].
7.3. p53 and Radiotherapy. Tumor cell death following
exposure to radiotherapy occurs by apoptosis and is a
p53-dependent event [94]. Preclinical studies were realized
on immunocompromised mice engrafted with fibrosarcoma
tumors expressing a functional or TP53-deficient gene.
Tumors with functional TP53 contained a large proportion
of apoptotic cells and regressed after treatment with gamma
radiation or adriamycin. p53-deficient tumors treated with
the same regimens continued to enlarge and contained few
apoptotic cells. Reduced levels of functional p53 would
prevent radiotherapy-induced cell death, while mutant p53
is a marker for resistance. The defects in apoptosis due to
inactivation of p53 can produce treatment-resistant tumors,
suggesting that p53 status could be important in determining
tumor response [95].
In conclusion, TP53 status shows a strong prognosis
impact and this could be useful in the choosing the best treat-
ment for breast cancer. Generally, TP53mutated is associated
with a poor response to chemotherapy, hormonotherapy or
radiotherapy. Discordant studies concerning its predictive
value exist, and this is linked to method of detection of
TP53 status. We show that FASAY test and sequencing of
TP53 are better than immunohistochemistry to determine
if TP53 is mutated or not. Prospective studies using these
two methods could better determine its predictive value
according to response to treatments.
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